ASND · Ascendis Pharma A/S
Market Cap
$16.41B
Shares
65.59M
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-13 | Q2 2026 Ascendis Pharma Earnings Conference Call | Earnings call |
| 2026-07-08 | ICCBH 2026: Week 104 ApproaCH Trial Radiographic Data | Event |
| 2026-07-08 | ICCBH 2026: Radiographic Data from Week 104 ApproaCH Trial | Event |
| 2026-06-13 | ENDO 2026: Week 182 PaTHway Data | Event |
| 2026-06-11 | 5-Year PaTH Forward Results | Event |
| 2026-05-06 | PES 2026 ApproaCH 2-Year Subgroup Data | Event |
| 2026-04-08 | New Data: Phase 2 COACH Trial Week 52 | Event |
| 2026-03-16 | ACMG 2026: ApproaCH Week 104 Data | Event |
| 2026-03-02 | YUVIWEL® (navepegritide) FDA Approval | Event |
| 2026-01-09 | 44th Annual J.P. Morgan Healthcare Conference Presentation | Conference |
| 2026-01-08 | COACH Trial Topline Week 52 Data | Event |
| 2025-07-12 | ENDO 2025: PaTHway 3-Year Data | Event |
| 2025-06-09 | COACH Trial Interim Topline Week 26 Data | Event |
Key facts
CIK
1612042
CUSIP
K08588103
13F (30d)
271 filings
268 filers
Visit website
Investor relations